Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00835523
: February 3, 2009
Last Update Posted
: June 14, 2012
University of Schleswig-Holstein
Information provided by (Responsible Party):
Georg Griesinger, University of Schleswig-Holstein
The aim of the study is to explore the concept of GnRH-agonist triggering in combination with elective cryopreservation of all 2PN oocytes at larger scale in a pragmatic clinical setting. The question asked is: "Does GnRH-agonist triggering and cryopreservation work", in terms of efficacy and safety, when applied to a larger cohort of patients, and by a number of different centres with different clinical routines.
OHSS Prevention by GnRH-agonist Triggering of Final Oocyte Maturation and Cryoperservation of All Two-pronucleate Oocytes in Women Undergoing Stimulation for IVF With Gonadotrophins and GnRH-analogues: a Prospective, Observational, Multicentric, Clinical Cohort Study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 39 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Indication for IVF with ICSI
Age < 40 years
< 4 failed previous IVF attempts with embryo transfer
ovarian stimulation with GnRH-antagonist and gonadotrophins
>20 follicles >11 mm in mean diameter or E2 >4500 pg/ml on the day , on which it was planned to administer hCG
willing to participate and able to consent
patient has not previously received GnRH-agonist as a trigger of final oocyte maturation